British Journal of Haematology · 1992 · 49 citations · 14 references
MedicineHematologyOncologyChemotherapyHematologic OncologyPediatric OncologyHematologic MalignanciesHigh-dose ChemotherapyLymphoid NeoplasmsPediatric ChemotherapyPediatric LeukemiasPediatric LymphomasChemotherapy Dose IntensityIrradiation EffectsLymphoma ChemotherapyPediatric Cranial IrradiationProphylactic Cranial IrradiationRelapsed LeukemiaT-cell Lymphoblastic Lymphoma
Ninety-five unselected patients with stage III and IV T cell lymphoblastic lymphoma were treated according to the United Kingdom Children's Cancer Study Group protocol 8503. This was a continuous, intensive leukaemia type regimen including cranial irradiation (18 Gy in 10 fractions) and continuing chemotherapy for 2 years identical to the concurrent Medical Research Council ALL protocol. Four-year event-free survival was 65% (95% CI 50-80%) with no significant difference between stage III and stage IV cases. 4.2% of patients died of infection or non-tumour related events. Following relapse salvage was unlikely without high dose chemotherapy and bone marrow rescue. These results show an improvement over previous U.K. studies but we need to continue to search for subsets of patients with resistant disease for whom even more intensive therapy possibly combined with bone marrow rescue is required.
14
Childhood Non-Hodgkin's Lymphoma
James R. Anderson, John F. Wilson, R. D. T. Jenkin et al. · New England Journal of Medicine · 1983 · 327 citations
Medicine, Oncology, Pediatrics +13
Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy
Norma Wollner, Joseph H. Burchenal, Philip Lieberman et al. · Cancer · 1976 · 250 citations · Full text
Medicine, Oncology, Pediatrics +14
Cancer clinical trials: methods and practice
Ron Brookmeyer · Controlled Clinical Trials · 1985 · 179 citations
Monoclonal antibody characterization of surface antigens in childhood T- cell lymphoid malignancies
M Röper, WM Crist, Richard S. Metzgar et al. · Blood · 1983 · 129 citations · Full text
Medicine, Immunology, Oncology +16